MedTrace Logo

Cholestasis Reversal: Efficacy of IV Fish Oil

NCT00910104 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether Omegaven is effective in the treatment of parenteral nutrition associated liver disease (PNALD).

Conditions

  • Parenteral Nutrition Associated Liver Disease
  • Short Bowel Syndrome
  • Gastrointestinal Disease

Interventions

DRUG

Omegaven®

10% Omegaven® 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated

Sponsors & Collaborators

  • Mark Puder

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2019-01-23
Completion
2019-01-23

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00910104 on ClinicalTrials.gov